OA12871A - Use of vasopeptidase inhibitors in the treatment of nephropathy. - Google Patents

Use of vasopeptidase inhibitors in the treatment of nephropathy. Download PDF

Info

Publication number
OA12871A
OA12871A OA1200400333A OA1200400333A OA12871A OA 12871 A OA12871 A OA 12871A OA 1200400333 A OA1200400333 A OA 1200400333A OA 1200400333 A OA1200400333 A OA 1200400333A OA 12871 A OA12871 A OA 12871A
Authority
OA
OAPI
Prior art keywords
compound
formula
diabetic
rats
use according
Prior art date
Application number
OA1200400333A
Other languages
English (en)
Inventor
Stefan Schaefer
Wolfgang Linz
Markus Bleich
Jochen Huber
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of OA12871A publication Critical patent/OA12871A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA1200400333A 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy. OA12871A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen

Publications (1)

Publication Number Publication Date
OA12871A true OA12871A (en) 2006-09-15

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400333A OA12871A (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy.

Country Status (39)

Country Link
US (2) US6930103B2 (es)
EP (1) EP1519732B1 (es)
JP (1) JP4564354B2 (es)
KR (1) KR101072235B1 (es)
CN (1) CN100366254C (es)
AR (1) AR040343A1 (es)
AT (1) ATE548040T1 (es)
AU (1) AU2003280440B2 (es)
BR (1) BR0312250A (es)
CA (1) CA2490277C (es)
CR (1) CR7667A (es)
CY (1) CY1112905T1 (es)
DE (1) DE10229180A1 (es)
DK (1) DK1519732T3 (es)
EC (1) ECSP045513A (es)
ES (1) ES2383889T3 (es)
HK (1) HK1079435A1 (es)
HN (1) HN2003000193A (es)
HR (1) HRP20041212B1 (es)
IL (2) IL165935A0 (es)
MA (1) MA27281A1 (es)
MX (1) MXPA04012230A (es)
NO (1) NO334811B1 (es)
NZ (1) NZ537480A (es)
OA (1) OA12871A (es)
PA (1) PA8576501A1 (es)
PE (1) PE20040582A1 (es)
PL (1) PL218070B1 (es)
PT (1) PT1519732E (es)
RS (1) RS52478B (es)
RU (1) RU2336080C2 (es)
SI (1) SI1519732T1 (es)
SV (1) SV2004001560A (es)
TN (1) TNSN04262A1 (es)
TW (1) TWI326215B (es)
UA (1) UA82845C2 (es)
UY (1) UY27869A1 (es)
WO (1) WO2004002492A1 (es)
ZA (1) ZA200409382B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69211133T2 (de) * 1991-03-01 1996-10-31 Zeria Pharmaceutical Co., Ltd., Tokio/Tokyo Indan-derivate als thromboxan-antagonisten
CA2078758C (en) * 1991-09-27 2003-12-09 Alan M. Warshawsky 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69317764T2 (de) * 1992-02-14 1998-07-30 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
JPH09510476A (ja) * 1994-03-24 1997-10-21 メリル・フアーマシユウテイカルズ・インコーポレイテツド 低コレステロール血性、抗アテローム性動脈硬化性および低トリグリセライド血性のアミノアセチルメルカプト誘導体
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
EE03524B1 (et) 1995-12-27 2001-10-15 Yoshitomi Pharmaceutical Industries, Ltd. Vahend diabeedi komplikatsioonide profülaktikaks ja raviks
CA2382549C (en) * 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
CZ299708B6 (cs) * 2001-04-12 2008-10-29 Sanofi - Aventis Deutschland GmbH Merkaptoacetylamidové deriváty, zpusob jejich prípravy a farmaceutické prostredky s jejich obsahem k ošetrování kardiovaskulárních onemocnení
AU2002355419A1 (en) * 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace

Also Published As

Publication number Publication date
HRP20041212A2 (en) 2005-06-30
DK1519732T3 (da) 2012-06-18
AU2003280440B2 (en) 2009-07-16
CN1665512A (zh) 2005-09-07
DE10229180A1 (de) 2004-01-29
MXPA04012230A (es) 2005-02-25
PA8576501A1 (es) 2004-02-07
NO334811B1 (no) 2014-06-02
CY1112905T1 (el) 2016-04-13
ECSP045513A (es) 2005-03-10
TWI326215B (en) 2010-06-21
MA27281A1 (fr) 2005-04-01
HRP20041212B1 (hr) 2013-06-30
IL165935A0 (en) 2006-01-15
CN100366254C (zh) 2008-02-06
BR0312250A (pt) 2005-04-26
TNSN04262A1 (en) 2007-03-12
JP2005533815A (ja) 2005-11-10
US20040058911A1 (en) 2004-03-25
RS52478B (en) 2013-02-28
EP1519732B1 (en) 2012-03-07
CA2490277A1 (en) 2004-01-08
SI1519732T1 (sl) 2012-05-31
SV2004001560A (es) 2004-02-26
TW200406214A (en) 2004-05-01
KR101072235B1 (ko) 2011-10-12
CR7667A (es) 2005-06-16
ZA200409382B (en) 2006-01-25
PE20040582A1 (es) 2004-10-18
CA2490277C (en) 2011-11-01
UA82845C2 (en) 2008-05-26
KR20050013642A (ko) 2005-02-04
US6930103B2 (en) 2005-08-16
ES2383889T3 (es) 2012-06-27
HN2003000193A (es) 2004-10-27
ATE548040T1 (de) 2012-03-15
AU2003280440A1 (en) 2004-01-19
PL218070B1 (pl) 2014-10-31
US7514423B2 (en) 2009-04-07
JP4564354B2 (ja) 2010-10-20
EP1519732A1 (en) 2005-04-06
NZ537480A (en) 2005-11-25
AR040343A1 (es) 2005-03-30
PL372992A1 (en) 2005-08-08
US20050171090A1 (en) 2005-08-04
UY27869A1 (es) 2003-12-31
PT1519732E (pt) 2012-05-22
IL165935A (en) 2010-12-30
WO2004002492A1 (en) 2004-01-08
NO20050425L (no) 2005-01-25
RS100704A (en) 2007-02-05
RU2336080C2 (ru) 2008-10-20
HK1079435A1 (en) 2006-04-07
RU2005102087A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
KR101880692B1 (ko) 합성 트리테르페노이드 및 질병 치료시의 사용 방법
Luft et al. Calcium channel blockade with nitrendipine. Effects on sodium homeostasis, the renin-angiotensin system, and the sympathetic nervous system in humans.
Mendez et al. Atrial natriuretic peptide transcription, storage, and release in rats with myocardial infarction
Han et al. Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats
US20080020974A1 (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x
Nosadini et al. Kidney hemodynamics after ketone body and amino acid infusion in normal and IDDM subjects
US7514423B2 (en) Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases
JPH05255079A (ja) 酸化窒素生成の抑制方法
Gross et al. The treatment of hyponatraemia using vasopressin antagonists
Richards et al. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure
Chu et al. Hyperdynamic circulation of cirrhotic rats: role of substance P and its relationship to nitric oxide
CA2545802A1 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
Böhler et al. Effect of nifedipine and captopril on glomerular hyperfiltration in normotensive man
Orzikulova Features of Antihypertensive Therapy in Patients with Metabolic Syndrome
JP2002535369A (ja) 糖尿病を治療するための組成物及び方法
KR20110073575A (ko) 당뇨병성 신증의 치료제
WO2009051804A1 (en) Thiazolium compounds for treating or preventing diseases associated with insulin resistance
Kiriyama et al. Stimulatory effects of bombesin on plasma trypsin release and exocrine pancreatic secretion in dogs
Lisy et al. O-35: Blood pressure lowering, renin suppressing and natriuretic properties of a new designer peptide BD-NP
Adam et al. O-33: Omapatrilat (OMA) a vasopeptidase inhibitor prevents mortality and cardiovascular injury in salt sensitive hypertension in addition to but independent of blood pressure